Balo Andrew K's Form 4 filing
Dexcom Inc (DXCM) · filed Sep 13, 2021
- Accession no.
- 0001093557-21-000223
- Filed
- Sep 13, 2021
- Trade date
- Sep 9, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 12 non-derivative transactions. Open-market sales total $3.06M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Balo Andrew KCIK 0001323190 | Officer (*) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2021 | Common Stock | JOtherDisposed | −2,498 | $0.00 | $0 | 14,056 | Direct | |
| Sep 9, 2021 | Common Stock | JOtherAcquired | +2,498 | $0.00 | $0 | 13,150 | Indirect | |
| Sep 9, 2021 | Common Stock | SSaleDisposed | −1,248 | $541.36 | −$675,617.28 | 11,902 | Indirect | |
| Sep 9, 2021 | Common Stock | SSaleDisposed | −15 | $541.76 | −$8,126.4 | 11,887 | Indirect | |
| Sep 9, 2021 | Common Stock | SSaleDisposed | −273 | $541.33F6 | −$147,783.09 | 11,614 | Indirect | |
| Sep 9, 2021 | Common Stock | SSaleDisposed | −200 | $542.83F7 | −$108,566 | 11,414 | Indirect | |
| Sep 9, 2021 | Common Stock | SSaleDisposed | −50 | $543.66 | −$27,183 | 11,364 | Indirect | |
| Sep 9, 2021 | Common Stock | SSaleDisposed | −550 | $547.35F8 | −$301,042.5 | 10,814 | Indirect | |
| Sep 9, 2021 | Common Stock | SSaleDisposed | −750 | $548.24F9 | −$411,180 | 10,064 | Indirect | |
| Sep 9, 2021 | Common Stock | SSaleDisposed | −1,261 | $549.43F10 | −$692,831.23 | 8,803 | Indirect | |
| Sep 9, 2021 | Common Stock | SSaleDisposed | −1,200 | $550.36F11 | −$660,432 | 7,603 | Indirect | |
| Sep 9, 2021 | Common Stock | SSaleDisposed | −50 | $551.45 | −$27,572.5 | 7,553 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F6
This transaction was executed in multiple trades at prices ranging from $541.27 to $541.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F7
This transaction was executed in multiple trades at prices ranging from $542.55 to $543.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F8
This transaction was executed in multiple trades at prices ranging from $546.745 to $547.740. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $547.80 to $548.65. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F10
This transaction was executed in multiple trades at prices ranging from $548.93 to $549.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F11
This transaction was executed in multiple trades at prices ranging from $549.99 to $550.73. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
Remarks
*EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development